

# Development of TME responding Probody CD3xCEACAM5 T-cell engager

DAAN Biotherapeutics, Inc.



ONCOLOGY	Candidate
Product Type	Antibody
Indication	CEACAM5 positive solid tumor
Target	CEACAM5/CD3 bispecific T-cell engager(TCE)
MoA(Mechanism of Action)	<p><b>Probody T-cell engager with TACTIC® (Tumor tArgeting Conditionally acTivated T-Cell engager) platform</b></p> <p>Our TACTIC® platform is comprised of albumin-binding masking domain and tumor specific cleavable peptide linker. When Probody TCE with TACTIC® encounters specific proteases overexpressed near tumor tissue, albumin-binding masking domain is designed to be removed by proteases and then unmasked TCE can bind to specific tumor-associated antigen</p>
Competitiveness	<p><b>Competitive status of conditionally active TCE platform</b></p> <ul style="list-style-type: none"> <li>- Amunix: XPAT technology(AMX-818, HER2-targeting TCE, Phase 2)</li> <li>- Harpoon: ProTriTAC(HPN-328, DLL3-targeting TCE, Phase 2)</li> <li>- Janux: TRACTr(JANX-007, PSMA-targeting TCE, Phase 1)</li> <li>- Maverick: COBRA(TAK-186, EGFR targeting TCE, discontinued)</li> <li>- Zymeworks: PROTECT(ZW-171, Mesothelin-targeting TCE, Phase 1)</li> </ul>
Development Stage	Candidate
Route of Administration	Intravenous infusion, IV

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*